Eptifibatide Injection Shortage
Last Updated: April 19, 2024
Status: Current
Products Affected - Description
-
- Eptifibatide injection, Amneal, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70121-1003-01
- Eptifibatide injection, Amneal, 2 mg/mL, 10 mL vial, 1 count, NDC 70121-1002-01
- Eptifibatide injection, Baxter, 0.75 mg/mL, 100 mL vial, 1 count, NDC 00338-9558-10
- Eptifibatide injection, Eugia US, 0.75 mg/mL, 100 mL vial, 1 count, NDC 55150-0218-99
- Eptifibatide injection, Eugia US, 2 mg/mL, 10 mL vial, 1 count, NDC 55150-0219-10
- Eptifibatide injection, Eugia US, 2 mg/mL, 100 mL vial, 1 count, NDC 55150-0220-99
- Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70860-0305-51
- Eptifibatide injection, Sagent, 2 mg/mL, 10 mL vial, 1 count, NDC 25021-0409-10
Reason for the Shortage
-
- Accord has temporarily discontinued eptifibatide injection.
- Akorn ceased operations in February 2023.
- Amneal did not provide a reason for the shortage.
- Baxter states the shortage is due to increased demand.
- Eugia did not provide a reason for the shortage.
- Merck discontinued Integrilin in October 2020. Wholesalers may continue to sell inventory until product expires.
- Viatris has eptifibatide injection available.
- Sagent states the shortage is due to manufacturing delay.
- Slate Run has eptifibatide injection available.
Available Products
-
- Eptifibatide injection, Mylan Institutional (Viatris), 0.75 mg/mL, 100 mL vial, 1 count, NDC 67457-0631-10
- Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 10 mL vial, 1 count, NDC 67457-0629-10
- Eptifibatide injection, Mylan Institutional (Viatris), 2 mg/mL, 100 mL vial, 1 count, NDC 67457-0630-10
- Eptifibatide injection, Sagent, 0.75 mg/mL, 100 mL vial, 1 count, NDC 25021-0408-51
- Eptifibatide injection, Slate Run Pharmaceuticals, 0.75 mg/mL, 100 mL vial, 1 count, NDC 70436-0027-80
- Eptifibatide injection, Slate Run Pharmaceuticals, 2 mg/mL, 10 mL vial, 1 count, NDC 70436-0026-80
Estimated Resupply Dates
-
- Amneal has eptifibatide 0.75 mg/mL 100 mL vials and 2 mg/mL in 10 mL vials on long-term back order and the company cannot estimate a release date.
- Baxter has eptifibatide 0.75 mg/mL in 100 mL vials on back order and the company estimates a release date in June 2024.
- Eugia has all eptifibatide injection presentations on intermittent back order and the company is releasing supplies as they become available.
- Sagent has eptifibatide 2 mg/mL 10 mL vials on back order and the company cannot estimate a release date. The 0.75 mg/mL 100 mL vials (NDC 70860-0305-51) are also on back order and the company cannot estimate a release date.
Updated
Updated April 19, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. Created May 21, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.